Liquidia FY2023 net loss $78.5M ($1.21/sh); patent victory clears path for YUTREPIA launch

Liquidia Corp

Net loss $78.5M ($1.21/sh) vs $41.0M ($0.67/sh) in FY2022; R&D spend rose 122% to $43.2M.
Cash $83.7M at Dec 31, 2023; raised $100M in Jan 2024 via equity placement and debt amendment.
Federal Circuit denied United Therapeutics' rehearing request, upholding invalidity of '793 Patent; injunction removal awaited.
YUTREPIA ready for launch in PAH and PH-ILD after Tyvaso exclusivity expires March 31, 2024 and injunction lifted.
L606 Phase 3 PH-ILD study planned by end-2024; ASCENT enrollment (60 patients) ongoing with interim data expected.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Liquidia Corp reported full year ended December 31, 2023 results: revenue $17.5 million.

Period: full year ended December 31, 2023
Revenue: $17.5 million
Result: reported results

Exact text from the filing

$25.0 million. HCRx has now invested $67.5 million in non-dilutive capital from the $100 million originally contemplated from four tranches under the RIFA. Revenue was $17.5 million for the year ended December 31, 2023, compared with $15.9 million for the year ended December 31, 2022. Revenue related primarily to the sale of Treprostinil Injection under the

View on SEC.gov

700 earnings releases filed in the last 30 days. Browse all earnings releases →

Liquidia Corp filing history →

Source: SEC EDGAR

accession 0001104659-24-033684

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.